On a different note, clinical trial based studies of MET inhibitors (cabozantinib and crizotinib) demonstrated a positive effect on non-small cell lung cancers with least toxicity but in gastrointestinal tumors their efficacy is still questionable and is associated with poor survival prognosis and shorter progression free survival (PFS)34,36. This evidence concerns the gene MET and non-small cell lung carcinoma.